CSI Market
Sign In | Register

Amneal Pharmaceuticals Inc (AMRX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access AMRX quarterly Cash Flow →
The cash flow figures below highlight longer-term patterns in how Amneal Pharmaceuticals Inc manages cash inflows and outflows over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income127.93
Depreciation & amortization0.00
Amortization of Other Assets22.43
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase-1.06
R & D, Environmental and Other Expense0.00
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal0.00
Share-based Compensation31.95
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction23.91
Transaction Costs Paid By Parent-
Impairment Of Intangible Assets Excluding Goodwill22.78
Insurance Recoveries For Property And Equipment Losses-
Gain Loss From Reduction Of Tax Receivable Agreement Liability-
Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs223.57
Interest Rate Cash Flow Hedge Gain Loss Reclassified To Earnings Net1.23
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable-120.58
Increase (Decrease) in Accounts Payable and Accrued Liabilities21.32
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-19.16
Other Working Capital0.00
Other Noncash Income (Expense)4.73
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.93
Discontinued operations0.00
Net Cash flow from Operating Activities339.99
Investing Activities
Capital Expenditures-85.58
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments To Acquire Property Plant And Equipment Deposits-28.78
Payments For Asset Acquisitions-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Insurance Settlement, Investing Activities0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Sales of Business, Affiliate and Productive Assets0.00
Accounts payable0.00
Receivables0.00
Proceeds from Life Insurance Policies0.00
Other Net2.09
Discontinued operations0.00
Net Cash Flow from Investing Activities-112.26
Financing Activities
Short-term debt Net218.00
Other borrowing transactions-74.97
Long-term debt - borrowings2,694.75
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.96
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-184.55
Repayment Of Financing Obligation-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents118.42
Repayments Of Financing Obligation Related Party Debt-
Finance Lease Principal Payments-
Repayments Of Long Term Debt And Financing Lease Obligations-
Noncash Or Part Noncash Divestiture Amount Of Consideration Received-
Noncash Or Part Noncash Acquisition Value Of Assets Acquired-
Tax Distributions To Noncontrolling Interests-
Payments For Restricted Stock Unit Tax Vesting-
Tax Distribution To Non Controlling Interest-
Repayments Of Long Term Debt Revolving Credit Facility And Financing Lease Obligations-2,811.51
Payment Of Deferred Consideration For Acquisition Related Party-
Proceeds From Alliance And Collaboration Agreements6.37
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-31.53
Effect of exchange rate on cash flow-1.68
Discontinued operations0.00
Free Cash Flow254.42
Total Cash Flow194.52
4 historic quarters locked

Sign in to unlock the full Amneal Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Amneal Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 27, 2026
  • Source: amrx-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001723128-26-000011

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License